Uniqure NV QURE:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 5:42 PM EDT29.89
+0.01 (+0.03%)
+0.01 (+0.03%)Volume
38,335
Close
29.88+3.12 (+11.66%)
+3.12 (+11.66%)Volume
2,830,137
52 week range
8.73 - 71.50
- Open27.02
- Day High30.45
- Day Low26.90
- Prev Close26.76
- 52 Week High71.50
- 52 Week High Date10/28/25
- 52 Week Low8.73
- 52 Week Low Date03/03/26
Latest On Uniqure NV
Key Stats
- Market Cap1.884B
- Shares Out63.07M
- 10 Day Average Volume1.17M
- Dividend-
- Dividend Yield-
- Beta1.01
Latest On Uniqure NV
KEY STATS
- Open27.02
- Day High30.45
- Day Low26.90
- Prev Close26.76
- 52 Week High71.50
- 52 Week High Date10/28/25
- 52 Week Low8.73
- 52 Week Low Date03/03/26
- Market Cap1.884B
- Shares Out63.07M
- 10 Day Average Volume1.17M
- Dividend-
- Dividend Yield-
- Beta1.01
RATIOS/PROFITABILITY
- EPS (TTM)-3.51
- P/E (TTM)-8.51
- Fwd P/E (NTM)-6.85
- EBITDA (TTM)-173.75M
- ROE (TTM)-228.24%
- Revenue (TTM)18.093M
- Gross Margin (TTM)90.56%
- Net Margin (TTM)-1,154.42%
- Debt To Equity (MRQ)356.41%
EVENTS
- Earnings Date07/31/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREUniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing...
David Meek
Non-Executive Independent Chairman of the Board
Matthew Kapusta CPA
Chief Executive Officer, Executive Director
Christian Klemt CPA
Chief Financial Officer
Address
Paasheuvelweg 25a
Amsterdam
1105BP
Netherlands